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The  effectiveness  of  vaccines  to  mitigate  the  impact  of  annual  seasonal  inﬂuenza  epidemics  and  inﬂuenza
pandemics  has  been  well  documented.  However,  the  steady  increase  in  global  capacity  to  produce  annual
seasonal  inﬂuenza  vaccine  has  not  been  matched  with  increased  demand,  and  thus  actual  vaccine  produc-
tion.  Currently,  without  a signiﬁcant  increase  in  demand  for seasonal  inﬂuenza  vaccine,  global  capacity
will  be  far  from  able  to meet  even  the  essential  needs  for a monovalent  vaccine  in the  event  of a  severe
inﬂuenza  pandemic.  Global  commitment  to  the  development  of  inﬂuenza  vaccine  production  capacityaccine
nﬂuenza
easonal
roduction
was  renewed  at  a  consultation  leading  to  the  Second  Global  Action  Plan  on Inﬂuenza  Vaccines  (GAP) in
July  2011.  To  monitor  progress  on  the  GAP,  the  World  Health  Organization  has  carried  out  periodic  sur-
veys  of  inﬂuenza  vaccine  manufacturers.  This  latest  survey  compares  current  maximum  global  capacity
and  actual  production  of seasonal  inﬂuenza  vaccine  in  2011  with  data  from  surveys  carried  out  in 2009
l  inﬂ
nd,  b
aniza
cine manufacturers with established seasonal inﬂuenza vaccine
production capacity in 2011.1 The questionnaire requested each
manufacturer to report both its estimated total production capac-apacity and  2010;  analyses  globa
options  to  increase  dema
© 2012 World Health Org
. Introduction
The effectiveness of vaccines to mitigate annual seasonal
nﬂuenza epidemics and the potentially devastating impact of
nﬂuenza pandemics has been well documented. What is some-
imes less recognized is the intrinsic link between production
apacity for seasonal inﬂuenza vaccine – which tends to be aligned
ith demand by immunization programmes – and potential vac-
ine availability for pandemic inﬂuenza vaccination. Indeed, rapid
roduction of a pandemic inﬂuenza vaccine in the billions of doses
eeded to meet expected demand currently depends entirely on
lobal capacity to produce seasonal trivalent inﬂuenza vaccines.
The  Global Action Plan on Inﬂuenza Vaccines (GAP), published
n 2006, is a comprehensive strategy to reduce the global shortage
f inﬂuenza vaccines for seasonal epidemics and severe pandemics
n all countries through three main approaches: (1) increasing sea-
onal vaccine use; (2) increasing vaccine production capacity; and
3) research and development [1]. Since 2006, signiﬁcant progress
as been made: new and expanded facilities have been announced
n both developed and developing countries; the amount of antigen
equired per dose is now lower due to new adjuvants; production
ields have improved; and advances have been made with new
echnologies. Global commitment to the development of inﬂuenza
accine production capacity was renewed at a consultation leading
∗ Corresponding author at: Health Systems and Innovation, World Health Orga-
ization,  Avenue Appia 20, 1211 Geneva 27, Switzerland. Tel.: +41 22 791 35 91;
ax: +41 22 791 49 09.
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Open access unduenza  production  capacity  in  the  context  of  sustainability;  and  discusses
ased  on strong  evidence  of  public  health  beneﬁt.
tion. Published by Elsevier Ltd.
to the Second GAP in July 2011 [2]. To monitor progress on vaccine
production capacity, the World Health Organization (WHO)  has
carried out periodic surveys of inﬂuenza vaccine manufacturers.
The latest survey compares current maximum global capacity and
actual production of seasonal inﬂuenza vaccine in 2011 with data
from surveys carried out in 2009 and 2010 [3,4], analyses global
inﬂuenza production capacity in the context of sustainability, and
discusses options to increase demand, based on strong evidence of
public health beneﬁt.
2.  Methodology
New information on global seasonal inﬂuenza vaccine produc-
tion capacity was  collected via a survey conducted by WHO  from
December 2011 to April 2012. The questionnaire, developed in
Microsoft Excel®, was  sent electronically to all known (28) vac-
Open access under CC BY-NC-ND license.1 Abbott Biologicals; ADImmune Corporation; Baxter; Berna-Crucell; Biken; Bio
Farma; Cantacuzino Institute; Changchun Changsheng Life Sciences Limited;
Chemo-Sero-Therapeutic Research Institute; China National Biotec Group
(Changchun  Institute of Biological Products, Lanzhou Institute of Biological
Products  Co., Ltd., and Shanghai Institute of Biological Products); CSL; Dalian Aleph
Biomedical Co., Ltd.; Denka Seiken; GlaxoSmithKline Biologicals; Green Cross
Corporation;  Hualan Biological Bacterin Co., Ltd.; Institute of Virology, Vaccines and
Sera Torlak; Kitasato; MedImmune; Microgen; Novartis Vaccines and Diagnostics;
Omnivest;  Panacea Biotec; NPO Petrovax Pharm, LLC; Sanoﬁ Pasteur; Serum
Institute  of India; Sinovac Biotech; Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
er CC BY-NC-ND license.
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Region (EUR), 378 million doses (27%) in the Region of the Amer-
icas (AMR), 324 million doses (23%) in the Western Paciﬁc RegionJ. Partridge, M.P. Kieny 
ty and its actual production (in millions of doses) of 2011 trivalent
easonal Southern Hemisphere (SH) vaccine and/or 2011–2012
rivalent seasonal Northern Hemisphere (NH) vaccine by type of
ormulation [inactivated or live attenuated, non-adjuvanted or
djuvanted (with adjuvant type), and antigen content per dose].
anufacturers with multiple production facilities were requested
o report capacity and production data aggregated across the
ountries if the facilities were in the same WHO  Region. Manufac-
urers were requested to disaggregate these data by WHO  Region if
heir facilities were located in more than one WHO  Region. Informa-
ion on future vaccine production facilities was obtained through
he GAP programme at WHO.
. Results
Twenty-seven vaccine manufacturers (96%) responded to the
urvey. For the one manufacturer who did not respond, data pro-
ided in 2010 was used in the analysis, as no major change in the
ompany had taken place between 2010 and 2011. The estimated
lobal annual capacity for seasonal trivalent inﬂuenza vaccine pro-
uction was 1420 million doses, with 75% of this capacity dedicated
o NH vaccine production (Table 1). This represents an increase of
44 million doses (62%) over the previous estimates based on data
rom the 24 manufacturers with production capacity in 2009 [3].
.1. Seasonal inﬂuenza vaccine production
In 2011, 25 manufacturers representing 34 production facilities
roduced 620 million doses of seasonal trivalent inﬂuenza vac-
ine, which was an increase of 47 million doses (8%) from the 2009
stimated production of 573 million doses [4]. Twenty-three (68%)
acilities produced only NH vaccines and 11 (32%) produced both
H and SH vaccines. No facilities produced only SH vaccines. Three
anufacturers reported capacity to produce inﬂuenza vaccines, but
id not produce trivalent seasonal inﬂuenza vaccine in 2011.
able 1
apacity and actual production of seasonal trivalent inﬂuenza vaccine in 2009 and
011.
Vaccine Doses (millions)
2009 2011
Seasonal trivalent vaccine capacity 876 1420
Northern Hemisphere seasonal vaccine capacity 1069
Northern Hemisphere seasonal vaccine production 470a, 500b 534c
Inactivated Northern Hemisphere vaccine
produced for 2011/2012 season
506
15 g antigen for each component
(non-adjuvanted)
447
15 g antigen for each component (adjuvanted) 30
7.5 g antigen for each component
(non-adjuvanted)
14
5 g antigen for each component (adjuvanted) 14
Live attenuated Northern Hemisphere vaccine
produced for 2011/2012 season
29
Southern Hemisphere seasonal vaccine capacity 352
Southern Hemisphere seasonal vaccine production 112d, 73e 86f
Inactivated Southern Hemisphere vaccine
produced for 2011/2012 season
86
15 g antigen for each component
(non-adjuvanted)
79
15 g antigen for each component (adjuvanted) 7
Live attenuated Southern Hemisphere vaccine
produced for 2011/2012 season
0
a 2008/2009 season.
b 2009/2010 season.
c 2011/2012 season.
d 2009 season.
e 2010 season.
f 2011 season.ine 31 (2013) 728– 731 729
3.2. Northern Hemisphere seasonal inﬂuenza vaccine estimated
capacity  and actual production
The estimated global annual capacity for NH seasonal trivalent
inﬂuenza vaccine production in 2011 was  1069 million doses, while
the reported number of doses actually produced for the 2011–2012
season was  534 million doses, i.e. only 50% of global capacity. Of
actual NH vaccine production, the vast majority of doses (86%) were
the inactivated non-adjuvanted formulation. The estimated annual
production capacity in 2011 was  a 22% increase over the 876 million
doses estimated in 2009 [3], while actual NH production increased
7% in 2011 compared with the 2009 estimate [4].
3.3. Southern Hemisphere seasonal inﬂuenza vaccine estimated
capacity  and actual production
The reported global annual capacity for SH seasonal trivalent
inﬂuenza vaccine production in 2011 was 352 million doses, while
the reported number of doses actually produced for the 2011 sea-
son was  86 million doses, i.e. only 24% of global capacity. Only
doses of the inactivated formulation were produced, 92% of which
were non-adjuvanted. Actual SH production decreased 23% in 2011
compared with the 2009 estimate [3].
3.4. Current and future seasonal inﬂuenza vaccine production by
WHO  Region
In  2011 there were 21 countries with seasonal trivalent
inﬂuenza vaccine production capacity (Table 2). Production capac-
ity was  estimated as 691 million doses (48%) in the WHO  European(WPR), and 28 million doses (2%) in the South-East Asia Region
(SEAR) (Fig. 1). In terms of actual production, EUR produced nearly
AFR
0%
AMR
27%
EMR
0%
EUR
48%
SEAR
2%
WPR
23%
Fig. 1. Global production capacity of seasonal trivalent inﬂuenza vaccine in 2011
by WHO  Region. AFR, WHO  African Region: no trivalent seasonal vaccine produc-
tion  capacity in 2011. AMR, WHO  Region of the Americas: trivalent seasonal vaccine
production capacity in 2011 in Canada and the United States of America. EMR, WHO
Eastern Mediterranean Region: no trivalent seasonal vaccine production capacity
in  2011. EUR, WHO  European Region: trivalent seasonal vaccine production capac-
ity in 2011 in Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy,
Netherlands, Romania, Russian Federation, Serbia, Switzerland and United Kingdom.
SEAR, WHO  South-East Asia Region: trivalent seasonal vaccine production capacity
in 2011 in India and Indonesia. WPR, WHO  Western Paciﬁc Region: trivalent sea-
sonal vaccine production capacity in 2011 in Australia, China, Japan and Republic of
Korea.
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Table 2
Seasonal trivalent inﬂuenza vaccine production by WHO  Region in 2011.
WHO
Region
Number of countries
with  production
capacity in 2011
Additional countries with
production  capacity
planned  after 2011
Estimated production
capacity  of NH vaccine
(doses  in millions)
Actual production of NH
vaccine  2011/2012
season  (doses in millions)
Estimated production
capacity  of SH vaccine
(doses  in millions)
Actual production of SH
vaccine  2011 season
(doses  in millions)
AFR 0 1 0 0 0 0
AMR 2 2 282 131 96 28
EMR 0 2 0 0 0 0
EUR 13 2 514 252 177 54
SEAR 2 1 9 0.044 19 0
WPR 4 1 264 151 60 4
Total 21 9 1069 534 352 86
NH, Northern Hemisphere; SH, Southern Hemisphere; AFR, WHO  African Region: no trivalent seasonal vaccine production capacity in 2011; AMR, WHO  Region of the
Americas: trivalent seasonal vaccine production capacity in 2011 in Canada and the United States of America; EMR, WHO  Eastern Mediterranean Region: no trivalent
seasonal vaccine production capacity in 2011; EUR, WHO  European Region: trivalent seasonal vaccine production capacity in 2011 in Austria, Belgium, Czech Republic,
France, Germany, Hungary, Italy, Netherlands, Romania, Russian Federation, Serbia, Switzerland and United Kingdom; SEAR, WHO  South-East Asia Region: trivalent seasonal
vaccine  production capacity in 2011 in India and Indonesia; WPR, WHO  Western Paciﬁc Region: trivalent seasonal vaccine production capacity in 2011 in Australia, China,
Japan  and Republic of Korea.
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0% of the global supply of NH vaccine followed by AMR, WPR  and
EAR which produced 26%, 25% and <1% of global supply, respec-
ively. For SH vaccine, nearly 62% of global supply was produced in
UR followed by 33% in AMR  and 5% in WPR. No seasonal trivalent
nﬂuenza vaccine was produced in 2011 in the WHO  Regions of
frica (AFR) or the Eastern Mediterranean (EMR); however, capac-
ty is currently being developed in countries in these two regions
long with additional countries in AMR, EUR, SEAR and WPR  (Fig. 2).
. Discussion
This is the third survey undertaken as part of ongoing moni-
oring of the progress of WHO’s Global Action Plan for inﬂuenza
accines [1]. Since the start of the GAP, vaccine production
apacity has not only grown in terms of the estimated number of
oses that could be produced, but has also expanded geograph-
cally. In 2006 when the GAP was developed, only 17 countries
roduced seasonal inﬂuenza vaccine. By 2011, seasonal inﬂuenza
accine was produced in 21 countries, and 8 further low- or middle-
ncome countries (LMIC) plan production in the near future.and 2011 and production capacity planned after 2011.
This potential increase in seasonal inﬂuenza production in LMIC
can be attributed in part to the WHO  Technology Transfer Initia-
tive, launched in 2008 under the auspices of the GAP. To date,
WHO has awarded grants to manufacturers in 14 countries (Brazil,
China, Egypt, India, Indonesia, Islamic Republic of Iran, Kazakhstan,
Mexico, Republic of Korea, Romania, Serbia, South Africa, Thailand
and Viet Nam) to develop inﬂuenza vaccine manufacturing tech-
nology. Of these, manufacturers in four countries (India, Republic
of Korea, Romania and Thailand) have licensed pandemic vac-
cines, two  countries (Republic of Korea and Romania) have licensed
trivalent seasonal vaccines on the market, and the remaining manu-
facturers have vaccines in various stages of development. Although
this will lead to improved vaccine access in LMIC, the capacity of
the new GAP-supported facilities will be largely limited to covering
their essential needs and, at best, those of neighbouring countries,
unless signiﬁcant markets can be identiﬁed for the larger manufac-
turers. In addition, there remains a major imbalance in access for
some geographic areas of the world, particularly in Africa and the
Middle East.
Progress towards the GAP objective to increase global vac-
cine production capacity and simultaneously increase equitable
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ccess to vaccine in LMIC has been impressive. However, using
 simpliﬁed hypothesis that the production of one dose of sea-
onal trivalent vaccine is equivalent to three doses of monovalent
andemic vaccine, the estimated current annual production capac-
ty for a pandemic vaccine would be 4260 million doses. This
ould hypothetically meet the GAP short-term goal of enabling
roduction of enough vaccine to immunize two billion people
ith two doses of vaccine within six months, but is short of the
edium- and long-term goals of enabling production of enough
accine to immunize the world’s population. In addition, this esti-
ate is limited by several factors, including the assumption that
he antigen yield will be similar for seasonal and pandemic vac-
ines.
Maintaining and continuing to increase global vaccine produc-
ion capacity require concomitant increase in demand for seasonal
accination. In comparison with the 2009 estimate of 876 million
oses [3], the annual global capacity to produce trivalent sea-
onal inﬂuenza vaccine increased more than 1.6-fold or by 544
illion doses by 2011; however, actual production has remained
early the same at 613 million doses in 2009 [3,4] and 620 mil-
ion doses in 2011, suggesting a lack of increase in demand for
easonal inﬂuenza vaccine during this period. Without uptake of
easonal inﬂuenza vaccine in national immunization programmes,
ased on local burden of disease and cost-effectiveness, manufac-
urers will be compelled to reduce their capacity in the future, and
nvestment in the newer inﬂuenza vaccine facilities in develop-
ng countries may  not bear its full potential. Therefore, the GAP is
ocusing increasingly on the objective to increase seasonal vaccine
se through multiple activities, including assessment of disease
urden, assessment of current and planned seasonal vaccine use
nd potential pandemic vaccine demand, strengthening national
mmunization advisory committees, and supporting immunization
olicy development.
One  promising opportunity to accelerate progress in the uptake
f seasonal inﬂuenza vaccine is collaboration of the GAP with the
HO Pandemic Inﬂuenza Preparedness (PIP) framework [5]. The
andate of the PIP framework is to ensure equity in inﬂuenza
andemic preparedness and response through a beneﬁt-sharing
pproach. In addition to pre-arranged agreements with manufac-
urers to secure pandemic vaccine for procurement via WHO  for
eveloping countries, the GAP overall objectives will beneﬁt from
tudies on disease burden, cost-effectiveness, and the evidence-
ased use of seasonal inﬂuenza vaccine and adjuvants. Such studies
re fundamental to increase seasonal inﬂuenza uptake and to sus-
ain global inﬂuenza vaccine production capacity.
[ine 31 (2013) 728– 731 731
With a view to updating the 2005 WHO  recommendations on
the use of seasonal inﬂuenza vaccine, the Strategic Group of Experts
on immunization (SAGE) commissioned an evidence-based review
of disease burden and vaccine performance and safety in all age
and at-risk groups. Data were particularly sought from within
LMIC. Based on the results of the analysis, SAGE recommended that
pregnant women  should be the ﬁrst target group as they are at
substantial risk of severe disease [6]. The potential beneﬁts of vacci-
nating health-care workers, and young children for herd effects and
potentially improving childhood survival, were also acknowledged.
Other priority groups considered were the elderly, indigenous
populations and persons with high-risk conditions. The successful
implementation of these recommendations will require educa-
tional programmes and social messaging, along with year-round
availability of safe and efﬁcacious vaccines. However, the ultimate
impetus for countries to promote seasonal inﬂuenza vaccination
will depend on local epidemiology, capacity and cost-effectiveness.
GAP will therefore devote enhanced attention to these avenues in
order to translate evidence into increased seasonal inﬂuenza vac-
cine uptake.
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